8-K current report · filed Nov 10, 2026

Spero Therapeutics Inc (SPRO) 8-K Current Report: November 10, 2026

Item 5.02SPRO overview

Short answer

Spero Therapeutics Inc (SPRO) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Patrick Vink resigned November 10 after 11 years, without reported disputes, creating a Class II board vacancy.

Spero Therapeutics Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Patrick Vink resigned November 10 after 11 years, without reported disputes, creating a Class II board vacancy
  • William Ho appointed to fill the Class II seat, adding clinical development and immunotherapy expertise
  • Ho joins the Development Committee, potentially strengthening oversight of Spero’s therapeutic pipeline
  • Director compensation: $45,000 annual cash retainers plus an option for 100,000 shares vesting monthly over one year
  • Ho’s prior RAPT role included programs contributing to GSK’s $2.2 billion acquisition, enhancing his transaction and development credentials

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Spero Therapeutics Inc 8-K filings

Get the next SPRO 8-K as it lands

Follow SPRO for push alerts, or ask the research agent what this filing means.